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Background and Aims. Preventive strategies of congenital anomalies are basically relying on the systematic ongoing collection
and analysis of data and timely dissemination of information. The aim of this paper is to briefly report a critical review of a
surveillance system of congenital anomalies in a developing country, by describing the challenges and experience of the registry
since it began. Methods. Tabriz Registry of Congenital Anomalies (TRoCA) was mainly set up based on the guidelines provided
by the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) for data collection, coding, process,
analysis, use, and evaluation of the system. Findings. TRoCA has successfully achieved its main objective as a pilot model for
setting up a nationwide registry of congenital anomalies in the country.The programme has too succeeded in relation to its regional
objectives: epidemiological rates and data have been produced consistently for etiological investigations, methodological studies,
service provision, and preventive measures for selected anomalies. Conclusions. Our successful experience, as a small registry in a
developing country, might be of interest and useful to practitioners, policymakers of birth defects control programmes, andmainly
those willing to set up a monitoring system of congenital anomalies in similar areas.
1. Introduction
Birth defects are making a proportionally major contribution
to perinatal mortality, childhood morbidity, and disability in
many countries. Occurrence of congenital disorders varies
between different countries ranging from 2 to 10 percent of
births [1, 2].
The prevention of congenital anomalies requires prior
knowledge of the aetiology and causal factors involved.
Although aetiology is still largely unknown, preventivemeth-
ods are now available for about 60 percent of congenital
abnormalities [3, 4]. Preventive strategies, on the other hand,
are basically relying on the surveillance, systematic ongoing
collection and analysis of data, and timely dissemination
of information. To assure the quality of these measures,
critical review of the procedures for evaluation purposes has
previously been introduced for monitoring systems [5, 6].
The aim of this paper is to briefly report a critical review
of a monitoring system of congenital anomalies in Iran, by
describing the challenges and experience of the registry since
it began.
2. Methods
2.1. Tabriz Registry of Congenital Anomalies. In 2000, a
project was carried out in the Tabriz city of Iran to investigate
the epidemiology of congenital anomalies. The aim of the
study was to provide baseline information to set up a
regional registry of birth defects for the first time in the
country. This programme was then called Tabriz Registry of
Congenital Anomalies (TRoCA) [7]. Our programme was
also accepted in the International Clearinghouse for Birth
Defects Surveillance and Research (ICBDSR), and European
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network of registries for congenital anomalies (EUROCAT)
as a member of countries having an established registry for
birth defects [1, 2].
Some of the registry systems of the ICBDSR and EURO-
CAT members were studied in terms of data collection,
process, analysis, use, and evaluation of the system to deter-
mine the requirements for setting up a local registry in
Iran. The minimum requirements for the registry were also
determined.
TRoCA is located in Tabriz city run under the Tabriz
University of Medical Sciences. Tabriz is one of the three
major cities in Iran, located in the northwest region. Tabriz
University of Medical Sciences is one of the five top univer-
sities in the country providing medical and health services
for the population in the northwest of Iran. TRoCA has been
financially supported by local and national funds.
2.2. Objectives. Theprincipal aims of TRoCAprogramme are
to establish a monitoring system of congenital anomalies in
the region and to implement control and preventive tasks in
the area. It was primarily intended to use TRoCA framework
as a pilot model for setting up a surveillance of birth defects
in the whole country. Purposes of TRoCA are to
(i) register the occurrence of selected birth defects in the
region,
(ii) prepare epidemiological indexes to indicate the mag-
nitude and trends over time,
(iii) monitor emerging or unusually high occurrences of
congenital anomalies,
(iv) make valid data available to policymakers,
(v) plan and implement preventive and control strategies
to prevent selected anomalies,
(vi) evaluate prevention and control strategies.
2.3. The Registration Process and Methodology. Prenatal care
is routinely provided for every pregnant woman on a regular
basis (up to eight times) with 1–3 diagnostic sonographies
during pregnancy. If needed, further diagnostic procedures
(i.e., genetic tests for congenital anomalies, etc.) are per-
formed. Termination of pregnancies is permitted for a few
selected anomalies. TRoCA reports termination rate for
major malformations only. After birth, all children in three
hospitals involved in the programme are normally examined
by a gynaecologist, obstetrician, neonatologist, or pediatri-
cian at birth. They are followed up until hospital discharge
for general health status, maturity, and congenital anomalies.
The TRoCA programme covers about 15,000 births (annual
average) in the area with about 300–400 newborns with one
of the anomalies in this population. Background information
and basic characteristic data are gathered for all births in
TRoCA region. Some additional information (i.e., family
history, parity, parental age, residence, education, maternal
illness, gestational length, birth weight, and type of birth)
is also available for infants with anomaly and mothers.
Karyotype and autopsy are not routinely performed unless it
is requested as a necessity after full clinical investigation.
We use a “passive”method of data collection.The respon-
sible persons (as registrar) for data documentation are
midwives. A medical coder has been assigned in this pro-
gramme to code/classify the defects. The end users defined
the congenital anomalies for the purposes of this programme
based on the standard coding system of the International
Classification of Diseases (ICD) under one of the follow-
ing main headings according to the primary diagnosis of
anomaly:
(i) Nervous system anomalies;
(ii) Genitourinary tract and kidney;
(iii) Anomalies of limb;
(iv) Chromosomal anomalies;
(v) Cleft lip with/without palate;
(vi) Congenital heart disease;
(vii) Musculoskeletal and connective tissue anomalies;
(viii) Digestive system anomalies;
(ix) Eye and ear anomalies;
(x) Other anomalies.
Total prevalence is calculated by dividing the numerator (reg-
istered cases of congenital anomalies in the TRoCA region)
by the relevant denominator (total live and stillbirths in the
TRoCA region) for the same period of time. An infant/fetus
with more than one anomaly is counted once only in the
numerator. The main criteria of inclusion of fetal deaths or
stillbirths in data analysis are pathologic confirmation of the
defect provided by the hospitals. Time trend analysis, relative
frequencies, and confidence intervals are also calculated for
some statistical purposes. For more details of the methodol-
ogy, TRoCA publications may be searched.
2.4. Ethics. TRoCA activities have been approved by the
Ethics Committee of the Tabriz University of Medical Sci-
ences. Confidentiality and privacy of identity-related infor-
mation are strictly considered in every part of the data
gathering, handling, processing, registration, access, and re-
ports.
3. Findings
3.1. Uses of TRoCA in Relation to Its Objectives
3.1.1. Detection of Epidemics. To date, generally, our data
shows no epidemic of any of kinds of birth defects in the area.
However, an unusual increase occurred for the total preva-
lence of congenital anomalies in 2002 in the registry region.
We then identified that this happened due to an improvement
in case ascertainment.
3.1.2. Time Trends. As seen in Figure 1, there is a steady
increase in the occurrence of congenital anomalies in the
region over time. Total prevalence of anomalies is more than
tripled ranging from 104.6 (per 10,000 births) in 2000 to 326.5
(per 10,000 births) in 2014. During this period of time, early
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Figure 1: Time trend of prevalence of congenital anomalies (Tabriz,
Iran) (dotted line shows the total prevalence in average).
records show that nervous system and genitourinary tract
anomalies were the most frequent defects while later data
indicated that heart and limb defects are the most common
ones (Figure 2).
3.1.3. Estimates of Prevalence. A total of 261 024 births were
registered in the region over the study period including 258
153 (98.9%) live births and 2871 (1.1%) stillbirths. During this
period, 5870 cases with a primary diagnosis of congenital
anomaly were ascertained, representing an overall prevalence
rate of 224.9 per 10,000 births. Genitourinary tract and
kidney anomalies, limb defects, anomalies of nervous system,
and congenital heart diseases accounted proportionally for
more than 65 percent of anomalies in the region (Figure 3).
3.1.4. Geographical Variations. Table 1 shows the prevalence
(in 10,000 births) of selected congenital anomalies in 13
ICBDSR registries across the globe published in 2014 for the
data between 2007 and 2011 [2]. The rate of total limb reduc-
tion defects in TRoCA is almost nine times, in average, higher
than that of other regions. Tabriz displays almost similar rates
for other groups of birth defects compared to other registries,
although the rate of anencephaly, hydrocephaly, and cleft
palate is still high in the region while spina bifida shows a low
rate.
3.1.5. Special Studies. Data provided by TRoCA have resulted
in a study to estimate the missing frequency of congenital
cardiac anomalies at the time of delivery and birth in the
region. Accordingly, 59.1% of children with congenital heart
diseases were not identified at birth [8].
We found that the accuracy of family physicians in case
detection and diagnosis of congenital anomalies in rural areas
ismore than 98% [9].We also investigated the occurrence rate
(33 percent) of termination in pregnancies with congenital
anomalies [10], and association of folic acid consumption and
birth defects [11]. More other studies have been carried out
using our registry data. For details, TRoCA publications need
to be searched.
3.1.6. Response to the Needs and Services. In addition to
the registration of birth defects, TRoCA has extended its
activities to implement control and preventive services for
genetic disorders and congenital anomalies in the region.
This includes genetic services to families who have a history
of an anomaly/disorder in the family, and preconceptional
programmes for young couples. This new programme called
Tabriz Foundation for Public Health Genetics (TFPHG) was
launched in 2013 [12].
3.1.7. Etiological Studies. General information is routinely
collected for every neonate. Some exposure information is
also available of mothers of all malformed infants. Other
women giving births in the TRoCA maternity and children
hospitals with normal newborns routinely complete the
similar data form. They might be considered as matched
control group. Using these data of control group plus routine
statistics from general population [13], testing of etiological
hypotheses and investigation of the role of some exposures
are virtually possible in TRoCA registry.
3.2. Limitations of TRoCA
3.2.1. Epidemiological Pitfalls. TRoCA is always able to de-
scribe the distribution and occurrence of congenital anoma-
lies in its defined population (by time, place, and other influ-
encing factors). However, epidemiological reliability and rep-
resentativeness of the rates captured by the programme have
not been fully investigated yet.The timeliness of the informa-
tion provided by TRoCA is also still a matter of epidemiolog-
ical pitfall where the programme is able to release primary
information on the occurrence of congenital anomalies at
least one year after the data collection.
As indicated before, TRoCA programme monitors about
15,000 births (annual average) in the area with about 300–400
cases with one of the defects in the newborns. The very small
frequency and the rare nature of some groups of anoma-
lies influence the epidemiological power of the rates and
occurrence patterns of various types of congenital anomalies
provided by the programme.
3.2.2. Delayed Ascertainment. Multiple sources of case ascer-
tainment result in a true pattern of birth defects in the popu-
lation.The data of TRoCA comes mainly from twomaternity
hospitals plus a referral medical centre for sick children in the
region. Some anomalies are routinely not diagnosed until
some times after birth. For this reason, ascertainment of those
defects is inevitably delayed. Nearly 60% of children born
with congenital heart disease, for example, were not ascer-
tained byTRoCAat birth.Theywere then identified as having
heart defects in children hospital during the next 12 months
after birth [8]. The delayed ascertainment, therefore, appears
to be an inevitable part of the registry.
3.2.3. Variable Validity of Data over Time. At birth, nervous
system anomalies were ranked first in the TRoCA earlier
years’ data while the first rank belongs to congenital heart
defects in recent years’ records (Figure 2). The reason is
that the improvement of the diagnosis and identification of
congenital heart defects over time have resulted in a complete
ascertainment of these groups of anomalies in the registry.
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Figure 3: Prevalence of congenital anomalies (Tabriz, Iran).
This variation in the ascertainment over time appears to be
an inevitable limitation of every registry including TRoCA.
4. Discussion
4.1. Has the TRoCA Succeeded? Tabriz Registry of Congenital
Anomalies started its main activities in 2000. A nationwide
registry of congenital anomalies in Iran was then established
in 2012 based on the data, framework, and baseline structure
provided by TRoCA (as a pilot programme). It is therefore
believed that TRoCA has successfully achieved its main
objective as a pilot model for the whole country.
TRoCA has too seemingly succeeded in relation to its
regional objectives: annual prevalence rates have been pro-
duced consistently over years [7], geographical comparisons
have beenmade possible by linking the TRoCAwith interna-
tional programmes [1, 2], and TRoCA has provided data for
some specific investigations [10, 11], service provision for
selected anomalies [8], and created a validated tool for family
practitioners for case detection and diagnosis of birth defects
[9]. In response to the health care needs of high risk popu-
lation, TRoCA is implementing control and preventive ser-
vices for some genetic disorders and anomalies in the region
[12].
4.2. Main Challenges. TRoCA recorded a low rate for spina
bifida, high rates for anencephaly, hydrocephaly, and cleft
palate without cleft lip, and a very high rate of limb reduction
defects in the region. While TRoCA examines and reports
the annual rates of congenital anomalies consistently, we do
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not know for sure whether any change in these rates is due
to a true existence/absence of epidemics in the region, due to
the technical failure of our monitoring, or due to aetiologic
and environmental teratogens. We do not have any paral-
lel surveillance for environmental teratogens. The reasons
behind the high/low rates of some groups of anomalies are
still unclear. There need therefore for further investigations
for every selected anomaly with unusual rate of occurrence
in the area.
As a programme in a developing country, the condition of
antenatal screening procedures, detection and ascertainment
methods of defects, variable validity of the data, low cover-
age and small denominator population (due to the limited
sources of funding), small number of cases (due to the small
population covered), low power of the programme to find
rare defects, and no full follow-up plan for anomalies after
hospital discharge are still among the main limitations of
the registry.The lack of epidemiological power and represen-
tativeness should therefore be carefully considered in exam-
ining the rates and patterns of various types of congenital
anomalies, and when investigating for possible local causes
and influencing factors of birth defects in the area.
For evaluation purposes, we assess the strengths and
weaknesses of the TRoCA programme based on the major
evaluation components of a standardmonitoring system (i.e.,
simplicity, flexibility, acceptability, reliability, utility, sustain-
ability, timeliness, sensitivity, and representativeness).
TRoCA has, so far, relied on staff for whom this pro-
grammewas not their core duties. Allocating fully funded full
time individuals for TRoCA may help to solve some parts of
the above problems in its future activities.
It is concluded that as a small registry of congenital
anomalies in a developing country, although TRoCA is still
facing some challenges and problems, we believe that it has
been successful in achieving its main objectives. Our expe-
riences might be of interest and useful to practitioners, pol-
icymakers of birth defects control programmes, and mainly
those willing to set up a monitoring system of congenital
anomalies.
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